PreludeDx has appointed Edwin Hendrick as the company's chief commercial officer. He has more than 30 years of related commercial experience and was most recently at Biocept. Before that, he was at Decipher Biosciences, formerly called GenomeDx, and at Plus Diagnostics. Laguna Hills, California-based PreludeDx's main product is the DCISionRT risk assessment test for patients with ductal carcinoma in situ.
Cofactor is a large, structured listing of people, places, and things. Here you can find the description of each topic.